Abbott Receives FDA Approval For TriClip, First-Of-Its-Kind Device To Repair Leaky Tricuspid Heart Valve
Portfolio Pulse from Benzinga Newsdesk
Abbott (NYSE:ABT) has received FDA approval for TriClip, a novel device designed for the minimally invasive treatment of tricuspid regurgitation (TR), a condition affecting over 1.6 million people in the U.S. TriClip, which is delivered through a vein in the leg, offers a significant improvement in patients' quality of life by repairing the tricuspid valve without the need for open-heart surgery. Data from the TRILUMINATE Pivotal trial showed a marked improvement in TR grade and quality of life for patients treated with TriClip. This approval expands Abbott's portfolio of structural heart solutions, including the MitraClip for mitral regurgitation, further establishing the company's leadership in minimally invasive heart therapies.
April 02, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott's FDA approval for TriClip, a device for tricuspid regurgitation treatment, marks a significant advancement in minimally invasive heart therapies, potentially boosting Abbott's market position in structural heart solutions.
The FDA approval of TriClip is a significant milestone for Abbott, showcasing its commitment to innovation in structural heart disease treatment. This approval not only enhances Abbott's product portfolio but also strengthens its position in the market for minimally invasive heart therapies. Given the large affected population and the device's potential to improve quality of life significantly, this approval is likely to have a positive short-term impact on Abbott's stock price. The positive data from the TRILUMINATE Pivotal trial further supports the potential for widespread adoption and success of TriClip in the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100